BBS (? secretase Blocking Site) Ab -A novel target for Alzheimer's and ALS immunotherapy

Summary of the technology

BBS (? secretase Blocking Site) Ab -A novel target for Alzheimer's and ALS immunotherapy
Project ID : 10-2007-105

Details of the Technology Offer

THE TECHNOLOGY
BBS is a monoclonal antibody that binds specifically and blocks beta-secretase (BACE1) cleavage site on its substrate, APP. BBS inhibits Ab production, a hall-mark of AD and other neurodegenerative diseases such as ALS.
The mechanism of action of BBS is based on binding of the antibody at the cell surface before internalization to the early endosome where BACE cleaves the APP.
AD and ALS share several similar pathological aspects and mechanisms including aberrant protein aggregation, increased neurodegeneration, mitochondrial dysfunction, oxidative stress, transcriptional dysregulation, aberrant apoptosis, altered proteosomal function and several downstream targets that were reduced by BBS (GSK3, p53).
DATA-TO-DATE
AD: In triple transgenic mice model of AD (3x Tg-AD), BBS
· Decreases both intracellular Ab levels including toxic oligomers and reduction in total and phosphorylated tau levels.
· Increases the cognitive capabilities and reduces brain inflammation levels which accompany AD pathology
ALS: ALS SOD1G93A mice, BBS:
· Exerts beneficial effect in that overexpress mutant SOD1.
· Reduces APP, Aβ and SOD1 levels
· Reduces neuroinflammation
· Significantly prolongs life span
These results suggest that treatment of AD and ALS with BBS could be a promising neuroprotective strategy for treatment of these debilitating diseases
DEVELOPMENT STATUS
· CHO clone for the mice BBS antibody
· Analytical methods protocol (ELISA)
· cDNA of a humanized antibody
· humanized Ab hybridoma available
PATENT
Three patent families cover the antibodies and their use.

Project manager

Elisha Natan
Director BD

Project researchers

Beka Solomon
T.A.U Tel Aviv University, Life Sciences
Molecular Microbiology-Biotechnology

Related Keywords

  • Medicine, Human Health
  • Medical Technology / Biomedical Engineering
  • Virus, Virology / Antibiotics / Bacteriology
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Microbiology Technology
  • Bioinformatics Technology
  • Micro- and Nanotechnology related to Biological sciences
  • Monoclonal Antibodies and Hybridomas
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Bioinformatics Market
  • Therapeutic
  • Clinical Medicine
  • Life Sciences and Biotechnology
  • Antibodies
  • cns
  • Pharmaceutical Indications
  • cns
  • cns

About RAMOT at Tel Aviv University Ltd.

Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at the university to industry's attention. The company provides the legal and commercial frameworks for inventions made by TAU faculty, students and researchers, protecting discoveries with patents and working jointly with industry to bring scientific innovations to the market.

RAMOT at Tel Aviv University Ltd.

Never miss an update from RAMOT at Tel Aviv University Ltd.

Create your free account to connect with RAMOT at Tel Aviv University Ltd. and thousands of other innovative organizations and professionals worldwide

RAMOT at Tel Aviv University Ltd.

Send a request for information
to RAMOT at Tel Aviv University Ltd.

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support